# A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

> **NCT04400695** · PHASE3 · UNKNOWN · sponsor: **RemeGen Co., Ltd.** · enrollment: 366 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** RC48-ADC
- **DRUG:** Paclitaxel Injection
- **DRUG:** Docetaxel Injection
- **DRUG:** Vinorelbine Tartrate Injection
- **DRUG:** Capecitabine Tablets

## Key facts

- **NCT ID:** NCT04400695
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-29
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 366 (ESTIMATED)
- **Last updated:** 2024-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04400695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04400695, "A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04400695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*